Written by 8:59 PM Uncategorized

Bharat Biotech slams criticism of indigenous vaccine Covaxin; we are a global company, says CMD

Bharat Biotech, the Indian pharma company which has developed in the COVID-19 vaccine, on Monday  described the controversy as uncalled for. Several Opposition parties, including the Congress, have questioned the credibility of Bharat Biotech and the move to grant emergency use authorisation to Covaxin. 

Speaking during a virtual press conference, Bharat Biotech MD Krishna Ella sought to clear all doubts over the much awaited vaccine against coronavirus and asserted that he has no political connections.

“We are not just conducting clinical trials in India. We have done clinical trials more than 12 countries including UK. We are doing clinical trials in Pakistan, Nepal, Bangladesh and other countries. We are not just an Indian company, we are truly a global company,” he said. 

Underlining that his company has vast experience in the field, Bharat Biotech MD said that Indian companies are being portrayed in a wrong way infront of the world. 

“We are not a company without experience in vaccines. We have tremendous experience in vaccines. We are touching 123 countries. We are the only company that has got such extensive experience and extensive publication in review journals,” Krishna Ella said.

“Many people are gossiping everything in different directions to just backlash on Indian companies. That is not right for us, we don’t deserve that,” he added. 

Addressing the PC, Dr Ella said that the criticism against Covaxin just because it was an Indian vaccine was undue and hurtful. “India can innovate; it’s not a copycat country. We don’t deserve a backlash because we are an Indian company In India, we do everything systematically and yet we get bashing from the news media. A company has branded our vaccine as water. It hurts as a scientist and we don’t deserve that. Why is nobody questioning the UK trials? Because, Indian trials are easy to be bashed,” Dr Ella said.Addressing the PC, Dr Ella said that the criticism against Covaxin just because it was an Indian vaccine was undue and hurtful. “India can innovate; it’s not a copycat country. We don’t deserve a backlash because we are an Indian company In India, we do everything systematically and yet we get bashing from the news media. A company has branded our vaccine as water. It hurts as a scientist and we don’t deserve that. Why is nobody questioning the UK trials? Because, Indian trials are easy to be bashed,” Dr Ella said.

Dr Krishna Ella also slammed those who have claimed that Bharat Biotech has not maintained transparency in the development of the vaccine Covaxin.

“Many people say that I am not transparent in my data. I think people should have the patience to read on the internet and how many articles we have published. More than 70 articles have been published in various international journals,” he said.

When asked when will he be able to provide phase 3 data, Dr Ella said the phase 3 trial in India will be over in the next two-three days and the data should be available by February or March.

(Visited 5 times, 1 visits today)
Close
Bharat Biotech slams criticism of indigenous vaccine Covaxin; we are a global company, says CMD
Child rights panel takes cue from Nayak, makes 19-year-old CM for a day
Vaccine disparities raise alarm as Covid-19 variants multiply
Russia, Hungary in talks to allow Covid-19 vaccine to be produced in Hungary as well
Russia Says Its Sputnik V COVID-19 Vaccine 95% Effective
India coronavirus numbers explained, Nov 7: Delhi is now single largest contributor of cases
18-year-old Audi driver runs over, kills sleeping guard in Chennai
Where does Dawood Ibrahim live in Karachi? Pakistan has three addresses
CM Of Assam Thanks Akshay Kumar For Donating 1 Crore For Assam Flood Relief.